ABSTRACT
Objective To explore the clinical efficacy of treating pains suffered from metastatic bone cancer with composite kushen injection and pamidronate disodium injection.Methods The clinical information of 60 cases of metastatic bone cancer patients suffered with pains was collected retrospectively.Thirty patients were assigned to the treatment group and 30 to the control group according to the treatment they underwent.The control group were treated with pamidronate disodium injection for 3 cycle,the treatment group were additionaly treated with composite kushen injection.The differences of two groups cases were compared in respect of the relief of pains and the changes of performance status (PS) and the incidence of adverse effects after treatment for 3 cycles.Results The objective remission rate of bone pain was 60.0％ (18/30) in the treatment group,which was significantly higher than that of 30.0％ (9/30) in the control group was higher( x2 =5.455,P=0.020 ).The incidence of adverse effect was 40.0％ (12/30) in the treatment group and 46.6％ (14/30) in the control group,with no significant difference between the two groups( x2 =0.271,P =0.602).In the treatment group the performance status of patients was( 2.30 ± 0.70 ) after treatment,which was better than that of( 1.80 ± 0.80 )before treatment(t =15.000,P =0.042),wheras there was no significant difference on performance status in the control group.Conclusion Kushen injection has synergistic effect with pamidronate disodium injection in treating pains with matstatic bone cancer.It could improve the short term efficacy,and significantly relief the pain and improve the quality of life.
ABSTRACT
Objective To demonstrate the result that progression of disease and prognosis of gastrointestinal cancer patients are correlated with the expression of the cluster and the abundance of lost goodwill target (LGT) fingerprint. Methods To research the period of survival and the time of death, 61 patients treated by SELDI (Surface enhanced laser desorption/ionization-time of flight-mass spectrometer)were involved in. According to the fingerprint spectrum obtained by SELDI and the appearance of fingerprints of LGT, these patients were divided into four groups namely non-peak, single-peak, double-peak, tri-peak and multi-peak groups. By means of Multi-factor analysis of variance and Cox regression analysis of risk, we compare four groups each other so as to find out one group in which patients have the greatest risk of death.Results Among the fingerprint spectrums of patients suffered from gastrointestinal cancer, which were obtained by SELDI, the patients with negative expression of LGT had low risk of death, which were lower than those of single-peak and double-peak groups, especially lower than those of tri-peak and multi-peak groups;the risk of death among the tri-peak and multi-peak groups were much higher than single-peak, the difference had statistical significance (P ＜0.05), and the death rate is rather high. Conclusion Among the serums from cancer patients tested by SELDI, the expression of LGT with tri-peak and multi-peak suggested that patient' s state of illness is about to deteriorate. This kind of fingerprint spectrum can be regarded as positive indicators,and the negative expression of LGT suggested that patient will have a good prognosis with a very low risk of death in the near future.
ABSTRACT
Objective To analyze the disposition characteristic of LGT fingerprints and the related fingerprints for advanced gastric carcinoma patients when the LGT fingerprints changing. Methods SELDI and CM10 protein chip was used to detect the serum protein fingerprints of 81 cased of advanced gastric cancer patients. After 1 year follow-up, all the patients were detected by SELDI again. According to the expression condition of LGT fingerprints, the patients were divided into 4 groups: A group(LGT changing from negative to positive) 25 cases, B group (LGT changing from positive to negative) 15 cases, C group (LGT fingerprints keeping negative) 29 cases and D group (LGT fingerprints keeping positive) 12 cases. The influencing factor should be rejected. And the remaining fingerprints were LGT fingerprints' subtypes and therelated fingerprints. The different proteomic fingerprints were analyzed by Biomarker Wizard 3.1 Software.Results After rejecting the influencing fingerprints, the up-regulation fingerprints in A group were 11473, 11821, 11664, 11409, 11552 and 11947 (M/Z), and no down-regulation fingerprints. In B group, 3264 was upregulation, and 6523, 11509, 11669, 11413, 11351 and 6483 were down-regulation. In C and D group, there was not statistically differential protein fingerprint. Conclusion M/Z up-regulating fingerprints including 11473, 11821, 11664, 11409, 11552 and 11947 can be regarded as the subtype of LGT when it changing from negative to positive; down-regulating including 11509, 11669, 11413 and 11351 can be regarded as the subtype of LGT when it changing from positive to negative; 3264 up-regulating and 6523 and 6483 downregulating can be regarded as the related fingerprints when LGT changing from positive to negative; and when LGT keeping negative or positive in patients with advanced gastric cancer, there was no differential protein fingerprints.
ABSTRACT
Objective To analyze the serum related proteomic fingerprints when Lost Goodwill Target (LGT) proteomic fingerprints drifting from negative to positive in the advanced lung adenocarcinoma patients. Methods The serum proteomic fingerprints of 31 advanced lung adenocarcinoma patients whose LGT fingerprints drifted from negative to positive were detected by SELDI and CM10 protein chip. More than 10 % cluster and M/Z values from 11,000+H to 12,000+H was regarded as LGT positive, otherwise as negative. Different fingerprints were screened by Biomarker Wizard 3.1 and Biomarker Wizard software and the decision tree model was established. Results There were 16 statistically different protein peaks when LGT fingerprints drifting from negative to positive, including 10 up-regulation proteomic fingerprints (M/Z:11531, 11483, 11686, 11394, 11822, 11323, 11911, 12450, 5811 and 5709) and 6 down regulation proteomic fingerprints( M/Z: 4126, 13927, 13784, 7001, 1959 and 2741). Conclusion By SELDI and CM10 protein chip detection, up-regulating fingerprints of M/Z 11531, 11483, 11686, 11394, 11822 and 11323 were regarded as the subtype of LGT when it drifting from negative to positive, while up-regulation of M/Z 11911,12450, 5811 and 5709 and down-regulating of M/Z 4126, 13927, 13784, 7001 and 1959 were regarded as the related fingerprints when LGT drifting from negative to positive. The above different fingerprints are constituted of the fingerprints library when LGT fingerprints drifting from negative to positive and it will provide a platform for studying the LGT proteins.
ABSTRACT
Objective To investigate the expression of CEA, NSE and CYFRA21-1 in lung cancer, and the significance of combined determination of three tumor markers in the detection of lung cancer. Methods CEA, NSE and CYFRA21-1 levels in serum of 65 patients with lung cancer, 50 patients with benign lung diseases and 38 normal adults were measured by enzyme linked immunosorbent assay (ELISA). The association of CYFRA21-1, NSE, and CEA level with the type of lung cancer in pathology were also studied. Results In comparison, the serum levels of CEA, CYFRA21-1 were increased more obviously in patients with lung cancer than that of patients with benign lung diseases and the normal adults (P<0.01). The levels of serum and the sensitivity of CEA, NSE and CYFRA21-1 were related to pathology type. The sensitivity and specificity increased by combined measurement of CEA, NSE, and CYFRA21-1. Conclusion These findings suggest that the serum CEA, NSE and CYFRA21-1 levels is increased in patients with lung cancer, and the increasing extents is not same in lung cancer with different pathology types. CEA, NSE and CYFRA21-1 are significant in adjuvant diagnosis of lung cancer.
ABSTRACT
Objective Verification of the serum proteomic fingerprints of NSCLC (non-small cell lung cancer) patients related to their advantage in Gefitinib therapy. Methods 27 NSCLC patients who have been treated with Gefitinib for more than 1 month and attained certain efficacy were taken for examination. They were divided into 3 groups, CR+PR, SD and PD, according to the evaluation criteria of solid tumor curative efficacy. All patients received SELDI (SELDI-TOF-MS surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technique) inspection before treatment with Gefitinib. The shifting procedure was based on the abundance of the fingerprint :"M/Z 8693 50H+". According to the abundance of this fingerprint founded, the patients were divided into 4 populations: 1. The advantage population (10 patients, abundance 10 %);2. The disadvantage population (7 patients, abundance≥30 %);3. Suspected population A (5 patients, abundance 11%-15 %);4. Suspected population B (5 patients, abundance 16～ 29%). The ratio of patients in each of the 3 groups (CR + PR, SD and PD) into each of the above 4 populations were analyzed. Results It showed that: 1. In the advantage population, the ratio dispersed from CR + PR group is 9/10, those from SD group is 1/10 and from PD is 0.2. In the disadvantage population, the ratio dispersed from CR + PR group is 1/7, those from SD group is 1/7 and from PD is 5/7. In the suspected A group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. 4. In the suspected B group, the ratio from CR + PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. Conclusion This fingerprint "M/Z 8693 50H+" with abundance 10% after SELDI inspection is the index choosing advantage patients suitable to receive Gefitinib therapy.